Summary
We have treated 102 Parkinson patients with bromocriptine for up to 6 years; most of these posed problems of management when referred to us. Forty-two continue to take bromocriptine, at a mean dose of 49 mg daily (range 10–160), in combination with some 50% of their previous optimal dose of levodopa (with or without a decarboxylase inhibitor). We consider the main indications for bromocriptine are severe dyskinesia, early morning dystonia, and “wearing off” reactions. Contraindications include hallucinations, delusions, substantial confusion, acute myocardial infarction, active peptic ulceration, and active pleuropulmonary disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Calne, D. B., Williams, A. C., Neophytides, A., Plotkin, C., Nutt, J. G., Teychenne, P. F.: Long-term treatment of Parkinsonism with bromocriptine. Lancet1, 735–738 (1978).
Corrodi, H., Fuxe, K., Hökfelt, T., Lidbrink, P., Ungerstedt, U.: Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. J. Phar. Pharmac.25, 409–412 (1973).
Duvoisin, R., Mendoza, M. R., Yahr, M. D., Sweet, R. D.: Bromocriptine as an adjuvant to levodopa. In: Symposium on Dopaminergic Ergot Derivatives and Motor Function, Stockholm, 1978, pp. 329–335. (Wenner-Gren Center International Symposium Series, Vol. 31.) Oxford: Pergamon Press. 1979.
Eisler, T., Hall, R. P., Kalavar, K., Calne, D. B.: Erythromelalgia-like eruption in Parkinsonian patients treated with bromocriptine. Neurology, in press (1981).
Fahn, S., Cote, L. J., Snider, S. R., Barrett, R. E., Isgreen, W. P.: Role of bromocriptine in the treatment of parkinsonism. In: Symposium on Dopaminergic Ergot Derivatives and Motor Function, Stockholm, 1978, pp. 303–312. (Wenner-Gren Center International Symposium Series, Vol. 31.) Oxford: Pergamon Press. 1979.
Godwin-Austen, R. G.: Bromocriptine compared with levodopa in parkinsonism. In: Symposium on Dopaminergic Ergot Derivatives and Motor Function, Stockholm, 1978, pp. 297–301. (Wenner-Gren Center International Symposium Series, Vol. 31.) Oxford: Pergamon Press. 1979.
Gopinathan, G., Calne, D. B.: Incontinence of urine with long-term bromocriptine therapy. Ann. Neurol.8, 204 (1980).
Gopinathan, G., Teräväinen, H., Dambrosia, J. M., Ward, C. D., Sanes, J. N., Stuart, W. K., Evarts, E. V., Calne, D. B.: Lisuride in parkinsonism. Neurology, in press (1981).
Graham, J. R., Suby, H. I., LaCoumpt, P. R., Sadowsky, N. L.: Fibrotic disorders associated with methysergide therapy for headache. N. Engl. J. Med.274, 359–368 (1966).
Grøn, U.: Clinical observations with bromocriptine in parkinsonism. In: Symposium on Dopaminergic Ergot Derivatives and Motor Function, Stockholm, 1978, pp. 343–347. (Wenner-Gren Center International Symposium Series, Vol. 31.) Oxford: Pergamon Press. 1979.
Hindle, W., Posner, E., Sweetnam, M. T., Tan, R. S. H.: Plural effusion and fibrosis during treatment with methysergide. Br. Med. J.1, 605 (1970).
Janssen, E. N. H.: Bromocriptine in levodopa response-losing Parkinsonism. Eur. Neurol.17, 92–99 (1978).
Lieberman, A., Kupersmith, M., Estey, E., Goldstein, M.: Treatment of Parkinson's disease with bromocriptine. N. Engl. J. Med.295, 1400 to 1404 (1976).
Lieberman, L., Leibowitz, M., Neophytides, A., Kupersmith, M., Pact, V., Walker, R., Zasorin, N., Goldstein, M.: The efficacy of a potent longacting dopamine agonist, pergolide, in Parkinson disease. Neurology30, 366 (1980).
Marsden, C. D., Jenner, P., Parkes, J. D., Price, P. A., Reavill, C.: Dosedependent locomotor effects of bromocriptine in animals and man-are some of its actions due to metabolites? In: Symposium on Dopaminergic Ergot Derivatives and Motor Function, Stockholm, 1978, pp. 313–318. (Wenner-Gren Center International Symposium Series, Vol. 31.) Oxford: Pergamon Press. 1979.
Rascol, A., Guiraud, B., Montastruc, J. L., et al.: Long-term treatment of Parkinson's disease with bromocriptine. J. Neurol. Neurosurg. Psychiatry42, 143–150 (1979).
Rinne, U. K.: Personal Communication (1980).
Rinne, U. K., Marttila, R., Sonninen, V.: Relationship between brain dopamine turnover and the therapeutic response to bromocriptine. In: Symposium on Dopaminergic Ergot Derivatives and Motor Function, Stockholm, 1978, pp. 319–324. (Wenner-Gren Center International Symposium Series, Vol. 31.) Oxford: Pergamon Press. 1979.
Stern, G., Lees, A., Shaw, K.: Ergot derivatives without levodopa in parkinsonism. In: Symposium on Dopaminergic Ergot Derivatives and Motor Function, Stockholm, 1978, pp. 337–339. (Wenner-Gren Center International Symposium Series, Vol. 31.) Oxford: Pergamon Press. 1979.
Teychenne, P. F., Jones, E. A., Ishak, K. G., Calne, D. B.: Hepatocellular injury with distinctive mitochondrial changes induced by lergotrile mesylate: a dopaminergic ergot derivative. Gastroenterology76, 575 to 583 (1979).
Teychenne, P. F., Pfeiffer, R. F., Bern, S. M., Calne, D. B.: Experiences with a new ergoline (CS 25-397) in parkinsonism. Neurology27, 1140–1143 (1977).
Teychenne, P. F., Pfeiffer, R. F., Bern, S. M., McInturff, D., Calne, D. B.: Comparison between lergotrile and bromocriptine in parkinsonism. Ann. Neurol.3, 319–324 (1978).
Thorner, M. O., Fluckiger, E. W., Calne, D. B.: Bromocriptine: A Clinical and Pharmacological Review, p. 189. New York: Raven Press. 1980.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Le Witt, P.A., Calne, D.B. Recent advances in the treatment of Parkinson's disease: The role of bromocriptine. J. Neural Transmission 51, 175–184 (1981). https://doi.org/10.1007/BF01664014
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01664014